Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: A randomized controlled trial

Obstetrics and Gynecology

Volumn 117, Issue 4, 2011, Pages 922-927

  Lee, Yoo Kyung ^a   Chung, Hyun Hoon ^a   Kim, Jae Weon ^a   Park, Noh Hyun ^a   Song, Yong Sang ^a   Kang, Soon Beom ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

LACTIC ACID; PLACEBO;

ADULT; ARTICLE; BREAST CANCER; CANCER SURVIVOR; CONTROLLED STUDY; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DYSPAREUNIA; ENDOMETRIUM; FEMALE; GEL; HUMAN; MAJOR CLINICAL STUDY; OVARY; PH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSVAGINAL ECHOGRAPHY; VAGINA PH; VAGINAL DRYNESS; VAGINITIS; VISUAL ANALOG SCALE;

ADMINISTRATION, INTRAVAGINAL; ADULT; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROGEN-ION CONCENTRATION; MIDDLE AGED; PATIENT SATISFACTION; SEVERITY OF ILLNESS INDEX; SURVIVORS; TREATMENT OUTCOME; VAGINAL CREAMS, FOAMS, AND JELLIES; VAGINITIS;

EID: 79953205240     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3182118790     Document Type: Article

References (23)

1. Leining MG, Gelber S, Rosenberg R, Przypyszny M, Winer EP, Partridge AH. Menopausal-type symptoms in young breast cancer survivors. Ann Oncol 2006;17:1777-82. (Pubitemid 44884052)
2. Crandall C, Petersen L, Ganz PA, Greendale GA. Association of breast cancer and its therapy with menopause-related symptoms. Menopause 2004;11:519-30. (Pubitemid 40362150)
3. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006;17: 584-7.
4. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, VanHaelst-Pisani C, Hammer AM, Rowland KM, Jr., et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophilbased vaginal moisturizer in women with breast cancer. J Clin Oncol 1997;15:969-73. (Pubitemid 27106279)
5. Boskey ER, Telsch KM, Whaley KJ, Moench TR, Cone RA. Acid production by vaginal flora in vitro is consistent with the rate and extent of vaginal acidification. Infect Immun 1999;67: 5170-5. (Pubitemid 29455288)
6. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. The Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD001500. DOI: 10.1002/14651858.CD001500.
7. Willhite LA, O'Connell MB. Urogenital atrophy: prevention and treatment. Pharmacotherapy 2001;21:464-80. (Pubitemid 32275275)
8. Morris M, Nicoll A, Simms I, Wilson J, Catchpole M. Bacterial vaginosis: a public health review. BJOG 2001;108:439-50. (Pubitemid 32607306)
9. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996;23:259-63. (Pubitemid 26000605)
10. Bachmann G. Urogenital ageing: an old problem newly recognized. Maturitas 1995;(22 suppl):S1-5. (Pubitemid 26021025)
11. Davila GW, Singh A, Karapanagiotou I, Woodhouse S, Huber K, Zimberg S, et al. Are women with urogenital atrophy symptomatic? Am J Obstet Gynecol 2003;188:382-8. (Pubitemid 36249975)
12. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24: 2137-50. (Pubitemid 46655601)
13. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351-8.
14. Utian WH. Ovarian function, therapy-oriented definition of menopause and climacteric. Exp Gerontol 1994;29:245-51. (Pubitemid 24211129)
15. van Geelen JM, van de Weijer PH, Arnolds HT. Urogenital symptoms and resulting discomfort in non-institutionalized Dutch women aged 50-75 years. Int Urogynecol J Pelvic Floor Dysfunct 2000;11:9-14. (Pubitemid 30107607)
16. Dennerstein L, Dudley E, Burger H. Are changes in sexual functioning during midlife due to aging or menopause? Fertil Steril 2001;76:456-60.
17. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27. (Pubitemid 36999703)
18. Rosenberg LU, Magnusson C, Lindstrom E, Wedren S, Hall P, Dickman PW. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res 2006;8:R11.
19. Nachtigall LE. Comparative study: replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178-80. (Pubitemid 24030700)
20. Langsford MJ, Dobbs FF, Morrison GM, Dance DA. The effect of introduction of a guideline on the management of vaginal discharge and in particular bacterial vaginosis in primary care. Fam Pract 2001;18:253-7. (Pubitemid 32514677)
21. Morris MC, Rogers PA, Kinghorn GR. Is bacterial vaginosis a sexually transmitted infection? Sex Transm Infect 2001;77: 63-8. (Pubitemid 32142791)
22. Guaschino S, De Seta F, Sartore A, Ricci G, De Santo D, Piccoli M, et al. Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2001;184:598-602. (Pubitemid 32234972)
23. Ray D, Goswami R, Banerjee U, Dadhwal V, Goswami D, Mandal P, et al. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care 2007;30:312-7. (Pubitemid 46198336)